0 XP   0   0   0

Ocular Therapeutix Inc










Financial Health of Ocular Therapeutix Inc




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Ocular Therapeutix Inc
Buy, Hold or Sell?

Should you buy, hold or sell Ocular Therapeutix Inc?

I guess you are interested in Ocular Therapeutix Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Ocular Therapeutix Inc

Let's start. I'm going to help you getting a better view of Ocular Therapeutix Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Ocular Therapeutix Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Ocular Therapeutix Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Ocular Therapeutix Inc. The closing price on 2022-12-07 was $2.8 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Ocular Therapeutix Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

1.1. Profitability of Ocular Therapeutix Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ocular Therapeutix Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -202.2% means that $-2.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -202.2%. The company is making a huge loss. -2
  • The TTM is -120.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-202.2%TTM-120.4%-81.8%
TTM-120.4%YOY-293.2%+172.9%
TTM-120.4%5Y-1,550.5%+1,430.1%
5Y-1,550.5%10Y-2,485.4%+935.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-202.2%-223.6%+21.4%
TTM-120.4%-281.7%+161.3%
YOY-293.2%-344.8%+51.6%
5Y-1,550.5%-450.1%-1,100.4%
10Y-2,485.4%-541.0%-1,944.4%
1.1.2. Return on Assets

Shows how efficient Ocular Therapeutix Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • -15.3% Return on Assets means that Ocular Therapeutix Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ocular Therapeutix Inc:

  • The MRQ is -15.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.3%TTM-8.7%-6.6%
TTM-8.7%YOY-8.5%-0.2%
TTM-8.7%5Y-17.4%+8.8%
5Y-17.4%10Y-16.3%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.3%-9.9%-5.4%
TTM-8.7%-8.9%+0.2%
YOY-8.5%-9.3%+0.8%
5Y-17.4%-11.7%-5.7%
10Y-16.3%-12.7%-3.6%
1.1.3. Return on Equity

Shows how efficient Ocular Therapeutix Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • -52.3% Return on Equity means Ocular Therapeutix Inc generated $-0.52 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ocular Therapeutix Inc:

  • The MRQ is -52.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-52.3%TTM-25.2%-27.1%
TTM-25.2%YOY-29.1%+3.8%
TTM-25.2%5Y-81.0%+55.8%
5Y-81.0%10Y-53.4%-27.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-52.3%-12.0%-40.3%
TTM-25.2%-11.5%-13.7%
YOY-29.1%-10.8%-18.3%
5Y-81.0%-14.2%-66.8%
10Y-53.4%-15.2%-38.2%

1.2. Operating Efficiency of Ocular Therapeutix Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ocular Therapeutix Inc is operating .

  • Measures how much profit Ocular Therapeutix Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • An Operating Margin of -187.1% means the company generated $-1.87  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -187.1%. The company is operating very inefficient. -2
  • The TTM is -106.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-187.1%TTM-106.6%-80.6%
TTM-106.6%YOY-274.7%+168.1%
TTM-106.6%5Y-1,473.5%+1,367.0%
5Y-1,473.5%10Y-2,401.0%+927.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-187.1%-207.3%+20.2%
TTM-106.6%-271.0%+164.4%
YOY-274.7%-325.9%+51.2%
5Y-1,473.5%-454.0%-1,019.5%
10Y-2,401.0%-537.1%-1,863.9%
1.2.2. Operating Ratio

Measures how efficient Ocular Therapeutix Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.80 means that the operating costs are $2.80 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 2.801. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.561. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.801TTM2.561+0.240
TTM2.561YOY3.010-0.449
TTM2.5615Y15.784-13.223
5Y15.78410Y57.948-42.164
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8012.871-0.070
TTM2.5613.504-0.943
YOY3.0103.604-0.594
5Y15.7845.132+10.652
10Y57.9486.371+51.577

1.3. Liquidity of Ocular Therapeutix Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.98 means the company has $4.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 4.975. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.417. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.975TTM6.417-1.442
TTM6.417YOY8.925-2.508
TTM6.4175Y6.348+0.069
5Y6.34810Y7.531-1.183
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9755.117-0.142
TTM6.4175.755+0.662
YOY8.9255.854+3.071
5Y6.3486.511-0.163
10Y7.5316.222+1.309
1.3.2. Quick Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.81 means the company can pay off $4.81 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 4.809. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.205. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.809TTM6.205-1.396
TTM6.205YOY8.704-2.499
TTM6.2055Y6.137+0.068
5Y6.13710Y8.907-2.771
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8094.284+0.525
TTM6.2054.664+1.541
YOY8.7044.787+3.917
5Y6.1375.218+0.919
10Y8.9075.182+3.725

1.4. Solvency of Ocular Therapeutix Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ocular Therapeutix Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ocular Therapeutix Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.71 means that Ocular Therapeutix Inc assets are financed with 70.8% credit (debt) and the remaining percentage (100% - 70.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.708. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.618. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.708TTM0.618+0.090
TTM0.618YOY0.654-0.036
TTM0.6185Y0.695-0.077
5Y0.69510Y0.488+0.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7080.278+0.430
TTM0.6180.277+0.341
YOY0.6540.306+0.348
5Y0.6950.367+0.328
10Y0.4880.403+0.085
1.4.2. Debt to Equity Ratio

Measures if Ocular Therapeutix Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 243.0% means that company has $2.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 2.430. The company is just not able to pay all its debts with equity.
  • The TTM is 1.685. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.430TTM1.685+0.745
TTM1.685YOY1.931-0.246
TTM1.6855Y2.850-1.165
5Y2.85010Y1.689+1.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4300.315+2.115
TTM1.6850.317+1.368
YOY1.9310.319+1.612
5Y2.8500.403+2.447
10Y1.6890.462+1.227

2. Market Valuation of Ocular Therapeutix Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ocular Therapeutix Inc generates.

  • Above 15 is considered overpriced but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A PE ratio of -13.21 means the investor is paying $-13.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -8.915. Company is losing money. -2
  • The MRQ is -13.213. Company is losing money. -2
  • The TTM is -53.152. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-8.915MRQ-13.213+4.298
MRQ-13.213TTM-53.152+39.940
TTM-53.152YOY156.111-209.264
TTM-53.1525Y5.924-59.077
5Y5.92410Y-29.343+35.268
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.915-8.986+0.071
MRQ-13.213-9.792-3.421
TTM-53.152-16.243-36.909
YOY156.111-20.876+176.987
5Y5.924-16.665+22.589
10Y-29.343-14.732-14.611
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Ocular Therapeutix Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 47.859. Seems overpriced? -1
  • The TTM is 59.443. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ47.859TTM59.443-11.584
TTM59.443YOY53.074+6.369
TTM59.4435Y691.650-632.207
5Y691.65010Y611.022+80.628
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ47.859-0.032+47.891
TTM59.4430.004+59.439
YOY53.0740.016+53.058
5Y691.6500.006+691.644
10Y611.0220.003+611.019

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ocular Therapeutix Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.91 means the investor is paying $6.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ocular Therapeutix Inc:

  • The EOD is 4.664. Neutral. Compare to industry.
  • The MRQ is 6.913. Seems overpriced? -1
  • The TTM is 5.900. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD4.664MRQ6.913-2.249
MRQ6.913TTM5.900+1.013
TTM5.900YOY15.601-9.701
TTM5.9005Y3.648+2.252
5Y3.64810Y7.305-3.657
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.6641.835+2.829
MRQ6.9132.006+4.907
TTM5.9002.774+3.126
YOY15.6013.453+12.148
5Y3.6482.713+0.935
10Y7.3052.402+4.903
2. Total Gains per Share

2.4. Latest News of Ocular Therapeutix Inc

Does Ocular Therapeutix Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Ocular Therapeutix Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-13
13:10
These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS ForecastsRead
2022-11-08
11:38
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)Read

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ocular Therapeutix Inc.

3.1. Institutions holding Ocular Therapeutix Inc

Institutions are holding 58.867% of the shares of Ocular Therapeutix Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30Opaleye Management Inc7.762810.8265597480000
2022-06-30SUMMER ROAD LLC7.7238100594476100
2022-06-30Vanguard Group Inc5.06520.00043898551-296855-7.0757
2022-09-30Deltec Asset Management LLC3.01912.3671232367325436012.292
2022-06-30Citadel Advisors Llc2.23990.00181723993316571.8706
2022-09-30Emerald Advisers, LLC1.95730.32251506456407542.7805
2022-06-30State Street Corporation1.83430.00031411827-293107-17.1917
2022-06-30Geode Capital Management, LLC1.75590.00081351425-12545-0.9197
2022-06-30Federated Hermes Inc1.54880.013119207256979291.5652
2022-09-30Emerald Mutual Fund Advisers Trust1.40590.28381082103373713.5771
2022-06-30MSD Partners, L.P.1.32040.6988101630210163020
2022-06-30Endurant Capital Management LP0.98771.0721760228-163735-17.7209
2022-06-30D. E. Shaw & Co LP0.97250.003574846513492721.9916
2022-06-30Altium Capital Management, LP0.9031.11869500000
2022-06-30Northern Trust Corp0.86740.0006667581-61579-8.4452
2022-06-30Cetera Investment Advisers0.77850.0383599150324005.7168
2022-06-30Banco Santander Central Hispano Sa0.72220.02985558845558840
2022-06-30UBS O'Connor LLC0.66640.036151288621288670.962
2022-06-30Bank of Montreal0.66420.001511195300258142.3449
2022-06-30BMO Capital Markets Corp.0.66420.0015111955111950
Total 42.8595116.815432987547+2869965+8.7%

3.2. Funds holding Ocular Therapeutix Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-10-31Vanguard Total Stock Mkt Idx Inv2.9980.0007230746200
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr2.9980.0009230746200
2022-10-31iShares Russell 2000 ETF2.1920.0114168711155100.3277
2022-10-31Vanguard Extended Market Index Investor1.49220.005114848187950.7717
2022-10-31iShares Russell 2000 Growth ETF0.80950.0233623043-2920-0.4665
2022-08-31Fidelity® Small Cap Index0.7780.0162598828133232.2755
2022-09-30Emerald Growth A0.65950.267650756400
2022-09-30Federated Hermes MDT Small Cap Core IS0.55240.1668425192-122844-22.4153
2022-09-30Federated Hermes MDT SCC Institutional0.55240.17425192-122844-22.4153
2022-09-30Principal SmallCap Growth I Instl0.53540.0815412090-740-0.1793
2022-09-30State St Russell Sm/Mid Cp® Indx NL Cl C0.51490.005539634000
2022-09-30Fidelity® Extended Market Index0.49730.0057382764-25904-6.3386
2022-09-30Federated Hermes MDT Small Cap Growth IS0.4710.259362542-260957-41.8536
2022-09-30Federated Hermes MDT SCG Institutional0.4710.2638362542-260957-41.8536
2022-09-30State St Russell Sm Cap® Indx NL Cl C0.38780.015298493107723.7439
2022-09-30NT R2000 Growth Index Fund - NL0.29690.0282228534-4076-1.7523
2022-09-30NT R2000 Index Fund - NL0.28550.0145219762-4133-1.846
2022-09-30Empower Small Cap Growth/Emerald SP0.25860.319719904900
2022-10-31Vanguard Russell 2000 ETF0.24680.011318999273063.9992
2022-09-30AST Small-Cap Growth0.22560.0728173668-65497-27.3857
Total 17.22281.738913256111-825166-6.2%

3.3. Insider Transactions

Insiders are holding 1.184% of the shares of Ocular Therapeutix Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-11-07Summer Road LlcBUY73283.56122089
2022-10-10Summer Road LlcBUY1000046104761
2022-09-29Summer Road LlcBUY188004.046094761
2022-09-27Summer Road LlcBUY1300004.686074761
2022-02-23Summer Road LlcBUY100004.8
2022-02-18Summer Road LlcBUY400005
2022-01-27Summer Road LlcBUY14775.2
2022-01-24Summer Road LlcBUY444005.31
2022-01-20Summer Road LlcBUY179485.7
2022-01-18Summer Road LlcBUY68076
2022-01-13Summer Road LlcBUY100006.2
2021-12-15Summer Road LlcBUY150006.22
2021-12-13Summer Road LlcBUY105106.5
2021-12-10Summer Road LlcBUY300006.65
2021-12-08Summer Road LlcBUY53006.75
2021-12-06Summer Road LlcBUY556006.13
2021-08-20Antony C MattessichBUY50009.89102900
2021-05-20Richard L Md LindstromSELL1000014.390000
2020-10-16Summer Road LlcBUY43710.48
2020-05-19Summer Road LlcBUY3636365.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ocular Therapeutix Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.197-0.105-46%0.269-173%0.007-3044%0.015-1413%
Book Value Growth---0.423-0.183-57%0.296-243%-0.306-28%-0.207-51%
Book Value Per Share--0.6000.858-30%0.986-39%0.521+15%0.583+3%
Book Value Per Share Growth---0.328-0.151-54%0.272-221%-0.304-7%-0.206-37%
Current Ratio--4.9756.417-22%8.925-44%6.348-22%7.531-34%
Debt To Asset Ratio--0.7080.618+15%0.654+8%0.695+2%0.488+45%
Debt To Equity Ratio--2.4301.685+44%1.931+26%2.850-15%1.689+44%
Dividend Per Share----0%-0%-0%-0%
Eps---0.314-0.185-41%-0.287-9%-0.243-23%-0.186-41%
Eps Growth---0.276-0.741+169%8.548-103%1.637-117%1.033-127%
Gross Profit Margin--1.4212.014-29%-0.281+120%1.074+32%1.072+33%
Net Profit Margin---2.022-1.204-40%-2.932+45%-15.505+667%-24.854+1129%
Operating Margin---1.871-1.066-43%-2.747+47%-14.735+687%-24.010+1183%
Operating Ratio--2.8012.561+9%3.010-7%15.784-82%57.948-95%
Pb Ratio4.664-48%6.9135.900+17%15.601-56%3.648+90%7.305-5%
Pe Ratio-8.915+33%-13.213-53.152+302%156.111-108%5.924-323%-29.343+122%
Peg Ratio--47.85959.443-19%53.074-10%691.650-93%611.022-92%
Price Per Share2.800-48%4.1505.023-17%15.323-73%7.310-43%8.143-49%
Price To Total Gains Ratio-14.214+33%-21.06714.469-246%98.092-121%-115.667+449%-105.143+399%
Profit Growth---22.416-73.475+228%759.860-103%144.873-115%68.637-133%
Quick Ratio--4.8096.205-22%8.704-45%6.137-22%8.907-46%
Return On Assets---0.153-0.087-43%-0.085-44%-0.174+14%-0.163+7%
Return On Equity---0.523-0.252-52%-0.291-44%-0.810+55%-0.534+2%
Revenue Growth---0.025-0.005-79%0.152-117%0.077-133%0.122-121%
Total Gains Per Share---0.197-0.105-46%0.269-173%0.007-3044%0.015-1413%
Total Gains Per Share Growth---0.138-0.492+256%-7.330+5200%-0.903+553%-0.913+560%
Usd Book Value--46229000.00069956500.000-34%81772500.000-43%42075200.000+10%45898550.000+1%
Usd Book Value Change Per Share---0.197-0.105-46%0.269-173%0.007-3044%0.015-1413%
Usd Book Value Per Share--0.6000.858-30%0.986-39%0.521+15%0.583+3%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.314-0.185-41%-0.287-9%-0.243-23%-0.186-41%
Usd Price Per Share2.800-48%4.1505.023-17%15.323-73%7.310-43%8.143-49%
Usd Profit---24188000.000-14836500.000-39%-22078750.000-9%-18856850.000-22%-13845925.000-43%
Usd Revenue--11965000.00012431500.000-4%9640500.000+24%5252300.000+128%2772525.000+332%
Usd Total Gains Per Share---0.197-0.105-46%0.269-173%0.007-3044%0.015-1413%
 EOD+3 -2MRQTTM+5 -28YOY+10 -235Y+16 -1710Y+15 -18

4.2. Fundamental Score

Let's check the fundamental score of Ocular Therapeutix Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.915
Price to Book Ratio (EOD)Between0-14.664
Net Profit Margin (MRQ)Greater than0-2.022
Operating Margin (MRQ)Greater than0-1.871
Quick Ratio (MRQ)Greater than14.809
Current Ratio (MRQ)Greater than14.975
Debt to Asset Ratio (MRQ)Less than10.708
Debt to Equity Ratio (MRQ)Less than12.430
Return on Equity (MRQ)Greater than0.15-0.523
Return on Assets (MRQ)Greater than0.05-0.153
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.900
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-09-302021-12-312022-03-312022-06-302022-09-30
Total Other Income Expense Net 22,186-7,98714,199-8,9085,291-4,1411,150-3,794-2,644



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets158,579
Total Liabilities112,350
Total Stockholder Equity46,229
 As reported
Total Liabilities 112,350
Total Stockholder Equity+ 46,229
Total Assets = 158,579

Assets

Total Assets158,579
Total Current Assets145,615
Long-term Assets145,615
Total Current Assets
Cash And Cash Equivalents 120,950
Net Receivables 19,802
Inventory 1,545
Other Current Assets 3,318
Total Current Assets  (as reported)145,615
Total Current Assets  (calculated)145,615
+/-0
Long-term Assets
Property Plant Equipment 11,200
Other Assets 1,764
Long-term Assets  (as reported)12,964
Long-term Assets  (calculated)12,964
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities29,269
Long-term Liabilities83,081
Total Stockholder Equity46,229
Total Current Liabilities
Short-term Debt 1,744
Accounts payable 5,308
Other Current Liabilities 21,614
Total Current Liabilities  (as reported)29,269
Total Current Liabilities  (calculated)28,666
+/- 603
Long-term Liabilities
Long term Debt Total 53,344
Capital Lease Obligations Min Short Term Debt4,610
Other Liabilities 25,127
Long-term Liabilities  (as reported)83,081
Long-term Liabilities  (calculated)83,081
+/-0
Total Stockholder Equity
Common Stock8
Retained Earnings -601,300
Capital Surplus 647,521
Total Stockholder Equity (as reported)46,229
Total Stockholder Equity (calculated)46,229
+/-0
Other
Capital Stock8
Cash and Short Term Investments 120,950
Common Stock Shares Outstanding 76,976
Common Stock Total Equity8
Current Deferred Revenue603
Liabilities and Stockholders Equity 158,579
Net Debt -61,252
Net Invested Capital 99,573
Net Tangible Assets 46,229
Net Working Capital 116,346
Short Long Term Debt Total 59,698



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
25,285
0
0
0
19,146
15,080
23,974
83,878
78,193
71,497
129,470
119,319
110,306
100,432
89,901
82,347
74,939
90,697
79,675
64,399
55,431
76,685
70,459
70,270
73,043
101,490
89,742
88,710
78,740
72,857
107,260
98,219
261,863
243,040
230,707
217,739
204,887
187,622
173,071
158,579
158,579173,071187,622204,887217,739230,707243,040261,86398,219107,26072,85778,74088,71089,742101,49073,04370,27070,45976,68555,43164,39979,67590,69774,93982,34789,901100,432110,306119,319129,47071,49778,19383,87823,97415,08019,14600025,285
   > Total Current Assets 
0
0
0
0
18,014
13,811
22,594
82,274
76,183
69,470
126,639
115,898
106,983
97,097
84,974
76,824
69,898
83,276
68,328
52,453
43,339
64,476
58,472
58,274
56,193
79,172
65,436
69,636
60,170
55,153
90,293
81,903
246,160
228,132
216,523
203,932
191,300
174,652
160,322
145,615
145,615160,322174,652191,300203,932216,523228,132246,16081,90390,29355,15360,17069,63665,43679,17256,19358,27458,47264,47643,33952,45368,32883,27669,89876,82484,97497,097106,983115,898126,63969,47076,18382,27422,59413,81118,0140000
       Cash And Cash Equivalents 
23,854
0
0
0
17,505
12,750
19,944
80,892
37,393
12,523
78,686
41,198
30,784
46,212
48,170
52,234
32,936
54,682
63,049
51,165
41,538
62,911
56,834
56,861
54,062
76,251
61,765
65,414
54,437
48,152
84,294
70,642
228,057
209,378
191,860
179,281
164,164
145,417
134,539
120,950
120,950134,539145,417164,164179,281191,860209,378228,05770,64284,29448,15254,43765,41461,76576,25154,06256,86156,83462,91141,53851,16563,04954,68232,93652,23448,17046,21230,78441,19878,68612,52337,39380,89219,94412,75017,50500023,854
       Short-term Investments 
60
0
0
0
60
60
60
60
37,435
54,900
45,036
72,445
74,280
49,244
35,717
23,513
35,209
25,697
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000003,00025,69735,20923,51335,71749,24474,28072,44545,03654,90037,4356060606000060
       Net Receivables 
0
0
0
0
269
306
61
54
329
352
164
189
193
227
223
243
250
244
211
278
226
170
285
240
201
276
615
1,114
2,548
3,429
2,874
7,779
12,252
13,631
18,734
19,552
21,135
23,207
20,482
19,802
19,80220,48223,20721,13519,55218,73413,63112,2527,7792,8743,4292,5481,11461527620124028517022627821124425024322322719318916435232954613062690000
       Inventory 
0
0
0
0
0
87
109
117
133
158
145
147
134
127
149
126
113
96
90
127
122
139
131
102
217
265
762
895
954
1,107
1,067
1,154
1,201
1,123
1,112
1,222
1,250
1,358
1,500
1,545
1,5451,5001,3581,2501,2221,1121,1231,2011,1541,0671,10795489576226521710213113912212790961131261491271341471451581331171098700000
   > Long-term Assets 
0
0
0
0
1,132
1,269
1,380
1,604
2,010
2,027
2,831
3,421
3,323
3,335
4,927
5,523
5,041
7,421
11,347
11,946
12,092
12,209
11,987
11,996
16,850
22,318
24,306
19,074
18,570
17,704
16,967
16,316
15,703
14,908
14,184
13,807
13,587
12,970
12,749
12,964
12,96412,74912,97013,58713,80714,18414,90815,70316,31616,96717,70418,57019,07424,30622,31816,85011,99611,98712,20912,09211,94611,3477,4215,0415,5234,9273,3353,3233,4212,8312,0272,0101,6041,3801,2691,1320000
       Property Plant Equipment 
785
0
0
0
904
1,041
1,152
1,376
1,782
1,799
2,603
3,193
3,095
3,107
3,199
3,795
3,313
5,693
9,619
10,218
10,478
10,595
10,373
10,382
10,236
15,704
17,542
17,310
16,806
15,940
15,203
14,552
13,939
13,144
12,420
12,043
11,823
11,206
10,985
11,200
11,20010,98511,20611,82312,04312,42013,14413,93914,55215,20315,94016,80617,31017,54215,70410,23610,38210,37310,59510,47810,2189,6195,6933,3133,7953,1993,1073,0953,1932,6031,7991,7821,3761,1521,041904000785
       Long-term Assets Other 
0
0
0
0
228
228
228
228
228
228
228
228
228
228
1,728
1,728
1,728
1,728
1,728
1,728
1,614
1,614
1,614
1,614
6,614
6,614
6,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7646,7646,6146,6141,6141,6141,6141,6141,7281,7281,7281,7281,7281,7282282282282282282282282282282280000
> Total Liabilities 
6,073
0
0
0
4,274
3,933
19,054
18,276
19,497
19,424
20,358
20,511
20,718
20,262
19,453
20,053
22,931
26,792
31,650
28,477
29,284
27,501
24,730
24,753
37,168
75,842
81,484
77,409
82,370
83,516
101,916
102,345
185,768
159,632
150,460
130,399
116,888
107,827
107,268
112,350
112,350107,268107,827116,888130,399150,460159,632185,768102,345101,91683,51682,37077,40981,48475,84237,16824,75324,73027,50129,28428,47731,65026,79222,93120,05319,45320,26220,71820,51120,35819,42419,49718,27619,0543,9334,2740006,073
   > Total Current Liabilities 
3,475
0
0
0
3,342
2,069
4,489
3,379
5,874
7,227
9,591
11,181
5,378
6,003
6,419
8,243
8,300
8,656
13,130
10,945
13,426
13,151
11,899
13,406
9,159
8,614
10,127
11,005
12,029
11,112
13,803
22,906
26,664
27,437
21,550
25,158
26,337
23,960
26,113
29,269
29,26926,11323,96026,33725,15821,55027,43726,66422,90613,80311,11212,02911,00510,1278,6149,15913,40611,89913,15113,42610,94513,1308,6568,3008,2436,4196,0035,37811,1819,5917,2275,8743,3794,4892,0693,3420003,475
       Short-term Debt 
0
0
0
0
0
0
1,085
0
1,354
2,860
4,370
5,883
15,272
1,161
2,466
3,772
1,549
897
2,444
3,993
5,545
6,071
6,082
6,094
0
675
0
0
0
2,074
4,146
6,206
8,290
9,711
1,487
1,554
1,624
1,696
1,771
1,744
1,7441,7711,6961,6241,5541,4879,7118,2906,2064,1462,07400067506,0946,0826,0715,5453,9932,4448971,5493,7722,4661,16115,2725,8834,3702,8601,35401,085000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
1,354
0
0
0
15,272
0
2,466
3,772
1,549
897
17,818
3,993
5,545
6,071
6,082
6,094
0
675
0
0
0
2,074
4,146
6,206
8,290
8,290
0
0
0
0
0
0
0000008,2908,2906,2064,1462,07400067506,0946,0826,0715,5453,99317,8188971,5493,7722,466015,2720001,35400000000
       Accounts payable 
583
0
0
0
545
996
1,525
649
1,316
2,195
2,812
1,624
1,957
2,063
1,611
1,680
2,116
3,754
6,307
2,599
3,571
3,477
2,137
2,777
2,965
3,902
4,044
3,461
3,268
2,839
2,650
3,238
2,709
4,152
3,881
4,246
4,592
3,420
3,703
5,308
5,3083,7033,4204,5924,2463,8814,1522,7093,2382,6502,8393,2683,4614,0443,9022,9652,7772,1373,4773,5712,5996,3073,7542,1161,6801,6112,0631,9571,6242,8122,1951,3166491,525996545000583
       Other Current Liabilities 
1,086
0
0
0
2,547
823
2,714
2,480
3,016
1,922
2,284
3,591
3,379
2,779
2,342
2,791
4,635
4,005
4,379
4,353
4,310
3,603
3,680
4,535
6,194
4,712
6,083
7,544
8,761
6,199
7,007
13,462
15,665
13,574
16,182
19,358
20,121
17,636
19,450
21,614
21,61419,45017,63620,12119,35816,18213,57415,66513,4627,0076,1998,7617,5446,0834,7126,1944,5353,6803,6034,3104,3534,3794,0054,6352,7912,3422,7793,3793,5912,2841,9223,0162,4802,7148232,5470001,086
   > Long-term Liabilities 
0
0
0
0
932
1,864
14,565
14,897
13,623
12,197
10,767
9,330
15,340
14,259
13,034
11,810
14,631
18,136
18,520
17,532
15,858
14,350
12,831
11,347
28,009
67,228
71,357
66,404
70,341
72,404
88,113
79,439
159,104
132,195
128,910
105,241
90,551
83,867
81,155
83,081
83,08181,15583,86790,551105,241128,910132,195159,10479,43988,11372,40470,34166,40471,35767,22828,00911,34712,83114,35015,85817,53218,52018,13614,63111,81013,03414,25915,3409,33010,76712,19713,62314,89714,5651,8649320000
       Long term Debt Total 
0
0
0
0
0
0
13,594
14,776
13,511
12,094
10,673
9,249
15,272
14,204
12,992
11,778
14,094
16,821
15,374
13,924
12,471
11,014
9,548
8,073
24,788
47,857
48,796
48,098
49,312
48,286
47,322
42,766
41,243
39,729
50,239
50,822
0
52,058
52,695
53,344
53,34452,69552,058050,82250,23939,72941,24342,76647,32248,28649,31248,09848,79647,85724,7888,0739,54811,01412,47113,92415,37416,82114,09411,77812,99214,20415,2729,24910,67312,09413,51114,77613,594000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-1,085
0
-1,354
-2,860
-4,370
-5,883
-15,272
-1,161
-2,466
-3,772
-1,549
-897
-2,444
-3,993
-5,545
-6,071
-6,082
-6,094
0
7,909
10,517
10,279
10,031
7,697
5,348
3,000
616
-1,121
6,770
6,355
5,924
5,472
4,999
4,610
4,6104,9995,4725,9246,3556,770-1,1216163,0005,3487,69710,03110,27910,5177,9090-6,094-6,082-6,071-5,545-3,993-2,444-897-1,549-3,772-2,466-1,161-15,272-5,883-4,370-2,860-1,3540-1,085000000
       Warrants
0
0
0
0
0
0
74,355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000074,355000000
       Long-term Liabilities Other 
0
0
0
0
0
0
852
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,909
9,493
9,206
8,905
8,590
8,256
7,909
19,548
19,169
18,770
18,355
0
18,575
17,999
18,143
18,14317,99918,575018,35518,77019,16919,5487,9098,2568,5908,9059,2069,4937,909000000000000000000852000000
       Deferred Long Term Liability 
0
0
0
0
0
0
119
121
112
103
94
81
68
55
42
32
537
1,315
3,146
3,608
3,387
3,336
3,283
3,274
3,221
11,462
13,068
9,100
12,124
15,528
32,535
28,764
98,313
73,297
59,901
36,064
0
13,234
10,461
11,594
11,59410,46113,234036,06459,90173,29798,31328,76432,53515,52812,1249,10013,06811,4623,2213,2743,2833,3363,3873,6083,1461,315537324255688194103112121119000000
> Total Stockholder Equity
19,212
0
0
0
14,872
11,147
4,920
65,602
58,696
52,073
109,112
98,808
89,588
80,170
70,448
62,294
52,008
63,905
48,025
35,922
26,147
49,184
45,729
45,517
35,875
25,648
8,258
11,301
-3,630
-10,659
5,344
-4,126
76,095
83,408
80,247
87,340
87,999
79,795
65,803
46,229
46,22965,80379,79587,99987,34080,24783,40876,095-4,1265,344-10,659-3,63011,3018,25825,64835,87545,51745,72949,18426,14735,92248,02563,90552,00862,29470,44880,17089,58898,808109,11252,07358,69665,6024,92011,14714,87200019,212
   Common Stock
0
0
0
0
0
2
0
2
2
2
2
2
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
5
6
6
8
8
8
8
8
8
8
8
8888888866555444444333332222222220200000
   Retained Earnings Total Equity-601,300-577,112-558,3460-541,954-544,611-536,130-539,251-453,639-441,695-405,127-383,615-357,598-338,820-314,367-297,243-279,844-264,834-251,030-237,265-224,163-208,596-189,902-173,879-161,057-151,461-140,016-129,176-118,539-107,015-97,006-89,428-81,474-74,180000000
   Accumulated Other Comprehensive Income 0000000000-10,019-10,01900-7,627-7,62700-5,341-5,341-4,8360-3,818-3,81800-2,939-2,93900-2,221-2,22100-1,768-1,6750000
   Capital Surplus 
0
0
0
0
0
0
4,745
147,074
148,122
149,077
216,133
217,361
218,830
220,184
221,897
223,344
225,889
253,813
256,618
260,082
263,409
300,210
310,559
325,357
333,114
340,011
347,074
368,894
379,980
394,463
447,033
449,507
615,338
619,530
624,850
629,286
0
638,133
642,907
647,521
647,521642,907638,1330629,286624,850619,530615,338449,507447,033394,463379,980368,894347,074340,011333,114325,357310,559300,210263,409260,082256,618253,813225,889223,344221,897220,184218,830217,361216,133149,077148,122147,0744,745000000
   Treasury Stock0000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
77,327
80,701
79,100
147,074
150,343
149,077
216,125
217,345
221,701
220,184
221,907
223,349
229,702
253,804
256,618
264,918
268,750
300,210
310,559
325,357
340,741
340,011
347,074
368,894
389,999
394,463
447,033
449,507
615,338
619,530
624,850
629,286
633,795
638,133
642,907
647,521
647,521642,907638,133633,795629,286624,850619,530615,338449,507447,033394,463389,999368,894347,074340,011340,741325,357310,559300,210268,750264,918256,618253,804229,702223,349221,907220,184221,701217,345216,125149,077150,343147,07479,10080,70177,3270000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue43,522
Cost of Revenue-4,406
Gross Profit39,11639,116
 
Operating Income (+$)
Gross Profit39,116
Operating Expense-117,153
Operating Income-78,037-78,037
 
Operating Expense (+$)
Research Development50,083
Selling General Administrative31,880
Selling And Marketing Expenses35,190
Operating Expense117,153117,153
 
Net Interest Income (+$)
Interest Income33
Interest Expense-6,671
Net Interest Income-6,638-6,638
 
Pretax Income (+$)
Operating Income-78,037
Net Interest Income-6,638
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-6,553-149,521
EBIT - interestExpense = -6,553
-6,553
118
Interest Expense6,671
Earnings Before Interest and Taxes (ebit)118118
Earnings Before Interest and Taxes (ebitda)2,539
 
After tax Income (+$)
Income Before Tax-6,553
Tax Provision--
Net Income From Continuing Ops-6,553-6,553
Net Income-6,553
Net Income Applicable To Common Shares-6,553
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses121,559
Total Other Income/Expenses Net71,4846,638
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
VBNK.TO
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBNK.TO.

VBNK.TO Daily Candlestick Chart
VCB.TO
3 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VCB.TO.

VCB.TO Daily Candlestick Chart
ZDH.TO
5 minutes ago

I found you a Golden Cross on the daily chart of ZDH.TO.

ZDH.TO Daily Candlestick Chart
MUS.TO
5 minutes ago

I found you a Golden Cross on the daily chart of MUS.TO.

MUS.TO Daily Candlestick Chart
VRIF.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VRIF.TO.

VRIF.TO Daily Candlestick Chart
ZLC.TO
8 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZLC.TO.

ZLC.TO Daily Candlestick Chart
XLY.TO
10 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of XLY.TO.

XLY.TO Daily Candlestick Chart
XGB.TO
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XGB.TO.

XGB.TO Daily Candlestick Chart
XCB.TO
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XCB.TO.

XCB.TO Daily Candlestick Chart
WILD.TO
12 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of WILD.TO.

WILD.TO Daily Candlestick Chart
VLNS.TO
13 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of VLNS.TO.

VLNS.TO Daily Candlestick Chart
TXG.TO
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TXG.TO.

TXG.TO Daily Candlestick Chart
IAF-PI.TO
17 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IAF-PI.TO.

IAF-PI.TO Daily Candlestick Chart
PNVL3.SA
22 minutes ago

I found you a Death Cross on the daily chart of PNVL3.SA.

PNVL3.SA Daily Candlestick Chart
XUTD.SW
24 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XUTD.SW.

XUTD.SW Daily Candlestick Chart
LABB.MX
26 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LABB.MX.

LABB.MX Daily Candlestick Chart
VGV.TO
28 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VGV.TO.

VGV.TO Daily Candlestick Chart
ZAPLOX.ST
28 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of ZAPLOX.ST.

ZAPLOX.ST Daily Candlestick Chart
WIL.V
29 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WIL.V.

WIL.V Daily Candlestick Chart
SOZAP.ST
37 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of SOZAP.ST.

SOZAP.ST Daily Candlestick Chart
BAT.JSE
45 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of BAT.JSE.

BAT.JSE Daily Candlestick Chart
EAGLE.PSE
53 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of EAGLE.PSE.

EAGLE.PSE Daily Candlestick Chart
TMET.V
54 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TMET.V.

TMET.V Daily Candlestick Chart
CGRA3.SA
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of CGRA3.SA.

CGRA3.SA Daily Candlestick Chart